Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.190
0.00 (0.00%)
Mar 3, 2026, 4:00 PM EST - Market closed

Spero Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
40.5547.98103.7853.5118.269.33
Revenue Growth (YoY)
-61.91%-53.77%93.95%193.10%95.67%-48.59%
Gross Profit
40.5547.98103.7853.5118.269.33
Selling, General & Admin
23.9323.725.5536.4841.721.44
Research & Development
61.7196.7651.4447.5964.5367
Other Operating Expenses
1.720.885.3111.63--
Total Operating Expenses
87.37121.3482.395.71106.2388.44
Operating Income
-46.82-73.3621.48-42.2-87.97-79.11
Interest Income
3.164.743.941.110.350.4
Interest Expense
----2.61-1.94-
Other Non-Operating Income (Expense)
0.110.06-0.01-2.72-0.190.43
Total Non-Operating Income (Expense)
3.274.83.92-4.22-1.790.83
Pretax Income
-43.55-68.5725.4-46.42-89.76-78.28
Provision for Income Taxes
-0.29--2.6---
Net Income
-43.26-68.5728-46.42-89.76-78.28
Net Income to Common
-43.26-68.5728-46.42-89.76-78.28
Shares Outstanding (Basic)
565453383122
Shares Outstanding (Diluted)
565453383122
Shares Change (YoY)
3.50%1.98%40.98%21.65%38.01%23.27%
EPS (Basic)
-0.79-1.270.43-1.23-2.91-3.52
EPS (Diluted)
-0.79-1.270.43-1.23-2.91-3.52
Free Cash Flow
-27.67-23.44-33-7.73-64.35-86.03
Free Cash Flow Per Share
-0.50-0.43-0.62-0.21-2.08-3.84
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-115.46%-152.91%20.70%-78.86%-481.87%-847.94%
Profit Margin
-106.68%-142.91%26.98%-86.74%-491.65%-839.01%
FCF Margin
-68.25%-48.87%-31.79%-14.45%-352.47%-922.07%
EBITDA
-46.82-73.3621.85-41.33-87.33-78.35
EBITDA Margin
-115.46%-152.90%21.05%-77.24%-478.34%-839.79%
EBIT
-46.82-73.3621.48-42.2-87.97-79.11
EBIT Margin
-115.46%-152.91%20.70%-78.86%-481.87%-847.94%
Effective Tax Rate
0.67%0.00%-10.23%0.00%0.00%0.00%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q